We have taken the initiation of the ProBio study in Switzerland as an opportunity to organise this one-day symposium, which is why the study has also become the eponym of our event. The ProBio study is a prospective randomised biomarker-driven clinical platform study to improve the quality of treatment in men with advanced prostate cancer.
In line with the concept of the ProBio study, international speakers will discuss new strategies in the treatment of metastatic prostate carcinoma at this symposium. Central to this are biomarkers such as "liquid biopsies" (ctDNA and CTCs), sequencing/ordering of therapeutics based on the latest molecular biology findings, mechanisms of resistance and new statistical concepts such as platform studies and adaptive randomisation. These new concepts are already finding their way into clinics and will be explained by experts and discussed in the clinical context during our event.